Once-daily ropinirole

Requip XL tablets (ropinirole prolonged release) offer a once-daily dosing schedule for the treatment of idiopathic Parkinson's disease in patients already taking ropinirole immediate-release tablets in whom adequate symptomatic control has been established.

Requip XL may be used alone (without levodopa) or in addition to levodopa to control ‘on-off’ fluctuations which might permit a reduction in the total daily dose of levodopa.

Substitution of Requip XL from ropinirole immediate-release tablets should be supervised by appropriate specialists in Parkinson’s disease.

View Requip XL drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Free resources on MIMS Learning keep you updated on COVID-19

Free resources on MIMS Learning keep you updated on COVID-19

MIMS Learning has a range of free resources for healthcare...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

First oral GLP-1 agonist launched for type II diabetes

First oral GLP-1 agonist launched for type II diabetes

Prescribers can now consider a GLP-1 agonist as an...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...